Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis

Current Treatment Options in Gastroenterology

Volumn 10, Issue 3, 2007, Pages 171-177

  Behm, Brian W ^b   Bickston, Stephen J ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; DRUG ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB; LIVE VACCINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PARACETAMOL; PLACEBO;

ANTIBODY PRODUCTION; CANCER RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FETOMATERNAL TRANSFUSION; HEART FAILURE; HUMAN; INFECTION; INJECTION SITE REACTION; LUPUS LIKE SYNDROME; MULTIPLE SCLEROSIS; NEOPLASM; OPTIC NEURITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; T CELL LYMPHOMA; TREATMENT DURATION; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS REACTIVATION;

EID: 34250679365     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0010-6     Document Type: Review

References (33)

1. Bamias G, Nyce MR, De La Rue SA, et al.: New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005, 143:895-904.
2. Farrell RJ, Shah SA, Lodhavia PJ, et al.: Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000, 95:3490-3497.
3. Cohen RD: Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 2001, 7(Suppl 1):S17-S22.
4. Ricart E, Panaccione R, Loftus EV, et al.: Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001, 96:722-729.
5. Lichtenstein G, Cohen RD, Feagan BG, et al.: Safety of infliximab in Crohn's disease: data from the 5000 - patient TREAT registry [abstract]. Gastroenterology 2004, 126:A54.
6. Gasche C, Scholmerich J, Brynskov J, et al.: A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000, 6:8-15.
7. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ: Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
8. Van den Brande JM, Braat H, van den Brink GR, et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
9. Zimmermann-Nielsen E, Agnholt J, Thorlacius-Ussing O, et al. Complement activation in plasma before and after infliximab treatment in Crohn disease. Scand J Gastroenterol 2003, 38:1050-1054.
10. Akobeng AK, Zachos M: Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2004, 1:CD003574.
11. Lichtenstein GR, Yan S, Bala M, et al.: Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004, 99:91-96.
12. Lichtenstein GR, Abreu MT, Cohen R, et al.: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940-987.
13. Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
14. Ljung T, Karlen P, Schmidt D, et al.: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004, 53:849-853.
15. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
16. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
17. Mahadevan U, Kane S, Sandborn WJ, et al.: Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005, 21:733-738.
18. Vasiliauskas EA, Church JA, Silverman N, et al.: Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006, 4:1255-1258.
19. Centers for Disease Control and Prevention. The immunocompromised traveler. Travelers' Health: Yellow Book [serial online]. http://www2.ncid.cdc.gov/travel/yb/utils/ ybGet.asp?section=special&obj=hivtrav.htm. Accessed February 27, 2007.
20. Rutgeerts P, D'Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
21. Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease Gastroenterology 2004, 126:402-413.
22. Biancone L, Orlando A, Kohn A, et al.: Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006, 55:228-233.
23. Thayu M, Markowitz JE, Mamula P, et al: Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005, 40:220-222.
24. Lichtenstein GR, Feagan BG, Cohen RD, et al.: Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
25. Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
26. Hommes D, Baert F, van Assche C, et al.: Management of recent onset Crohn's disease - a controlled randomized trial comparing step-up and top-down therapy [abstract]. Gastroenterology 2005, 129:371.
27. Rubenstein JH, Chong RY, Cohen RD: Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002, 35:151-156.
28. Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
29. Levy C, Tremaine WJ: Management of internal fistulas in Crohn's disease. Inflamm Bowel Dis 2002, 8:106-111.
30. Arseneau KO, Cohn SM, Cominelli F, et al.: Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001, 120:1640-1656.
31. Lawson MM, Thomas AG, Akobeng AK: Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006, 3:CD005112.
32. Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
33. Jarnerot G, Hertervig E, Friis-Liby I, et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-1811.